Patients with lupus and type 2 diabetes who receive glucagon-like peptide-1 receptor agonists have a lower risk of cardiac events and kidney disease progression compared to those using dipeptidyl peptidase 4 inhibitors. This is particularly important as the risk for cardiovascular disease and kidney disease is higher in patients with lupus. Data presented at ACR Convergence 2024 suggests that GLP-1 receptor agonists may have similar cardioprotective and nephroprotective benefits in patients with lupus and lupus nephritis as seen in other populations. Further investigation and prospective studies are needed to understand the potential benefits of GLP-1 receptor agonists in these patient populations.
Source link
Patients with lupus, type 2 diabetes at lower risk for MACE, VTE with GLP-1 vs DPP4 drugs
